

Figure 1A




Figure 1B




Figure 2A




FIG. 2B




Figure 3




Figure 4A

GM change from baseline in 24-hour UPCR over time

24-hour UPCR vs placebo Week 52	Anifrolumab		
	Combined	BR	IR
GMR (95% CI)	1.03 (0.62, 1.71)	1.10 (0.61, 1.99)	0.96 (0.55, 1.69)
P-value	0.905	0.741	0.895




Figure 4B

Percentage of patients with a CRR over time





Figure 4C

Time to CRR_{0.5} sustained through Week 52

Difference in CRR _{0.5} vs placebo	Anifrolumab	
	BR	IR
HR (95% CI)	0.46 (0.17, 1.15)	1.46 (0.71, 3.14)
Nominal P-value	0.103	0.311



Number of patients														
Anifrolumab BR	43	42	41	40	38	37	37	31	31	30	27	26	25	11
Anifrolumab IR	44	43	43	43	37	36	36	26	24	22	19	19	19	11
Placebo	45	42	39	37	32	31	30	24	23	22	18	18	18	7

Figure 5A




Figure 5B




Figure 6




Figure 7A




Figure 7B





Figure 8

Median percentage 21-gene type I IFN PD neutralization among IFNGS test-high patients



Number of patients

● Anifrolumab BR	39	35	38	30	13
□ Anifrolumab IR	45	43	40	35	21
◆ Placebo	37	35	34	31	10

Figure 9A




Figure 9B





Figure 10







Figure 11C




Figure 12




Figure 13A




Figure 13B





Figure 14

Figure 15




Figure 16A




Figure 16B




Figure 17A




Figure 17B




Figure 17C




Figure 18




Figure 19A




Figure 19B




Figure 20A




Figure 20B

IFNGS High SLE Subjects




Figure 21A




Figure 21B




Figure 22A




Figure 22B




Figure 23A




Figure 23B




Figure 24




Figure 25A




Figure 25B




Figure 25C




Figure 26A




Figure 26B




Figure 27




Figure 28A




Figure 28B




Figure 29A Baseline 24-hr UPCR > 3 mg/mg




Figure 29B Baseline 24-hr UPCR > 3 mg/mg




Figure 30




Figure 31




Figure 32




Figure 33




Figure 34




Figure 35




Figure 36A




Figure 36B




Figure 36C




Figure 37A

Urinary protein	NIH-AI	NIH-CI
Cathepsin D	+	+
MCP-1	+	+
OPG	+	+
TIMP-1	+	+
Adiponectin	+	
A2Macro	+	
Apo A-I	+	
Apo B	+	
Apo C-I	+	
Apo C-III	+	
CLU	+	
FRTN	+	
IgM	+	
IL-6R β	+	
LTF	+	
Neuropilin-1	+	
Omentin	+	
SAP	+	
RANTES	+	
vWF	+	
Apo A-II		+
Apo H		+
IGFBP-2		+
KIM-1		+
Vitronectin		+
IL-6 (Simoa)		+

Figure 37B

Urinary protein	eGFR	SLEDAI	SLEDAI-R	C3	C4	NIH-AI	NIH-CI	IFNGS
Apo A-II	-		+		+		+	
Apo B	-	+	+			+		
Apo C-I	-	+	+			+		
Cathepsin D	-	+				+	+	
EN-RAGE		+	+	-	-			+
Fibrinogen	-	+	+		+			
LTF	-	+	+			+		
MCP-1	-	+				+	+	
RANTES		+	+			+		+
IL-1 β (Simoa)		+	+	-	-			

Figure 38A

Urinary protein	eGFR	SLEDAI	SLEDAI-R	C3	C4	NIH-AI	NIH-CI	IFNGS
EN-RAGE		+	+	-	-			+
RANTES		+	+			+		+
BAFF			+					+
CD163			+					+
VCAM-1	-							+
MMP-3			+					+
B2M								+
GDF-15								+
ICAM-1								+
IL-1RA								+
IL-6R								+
LRG1								+
M-CSF								+
PECAM-1								+
TNF RI								+
TNFR2								+
uPAR								+



Figure 38B

Figure 39A**Figure 39B**

eGFR	SLEDAI-R	NIH-AI	IFNGS
Angiogenin	IgA	FRTN	B2M
ALP	Transferrin	IgM	GDF-15
Calbindin			ICAM-1
CCL15			IL-1ra
HCC-4			IL-6r
FABP, adipocyte			LRG1
IL-18			M-CSF
MMP-7			PECAM-1
NGAL			TNF RI
PPP			TNFR2
PARC			uPAR
TIMP-2			
YKL-40			




Figure 40A




Figure 40B

Figure 41A




Figure 41B




Figure 41C




Figure 42A




Figure 42B




Figure 42C




Figure 42D





Figure 43

Figure 44

Consensus	EVQLVQSGAEVKKPGESLKISCKGSGYIFTNYWIAWVRQMPGKGLSEMGIIYPGDSIDIRYSPSFQGGQVTISADKSITTAY	80
SEQ ID NO: 1_anifro-VH	EVQLVQSGAEVKKPGESLKISCKGSGYIFTNYWIAWVRQMPGKGLSEMGIIYPGDSIDIRYSPSFQGGQVTISADKSITTAY	80
SEQ ID NO: 3_anifro-HCDR1	-----NYWIA-----	50
SEQ ID NO: 4_anifro-HCDR2	-----IYPGDSIDIRYSPSFQG-----	31
SEQ ID NO: 5_anifro-HCDR2	-----	
SEQ ID NO: 10_anifro-HFc	-----	
SEQ ID NO: 11_anifro-HC	EVQLVQSGAEVKKPGESLKISCKGSGYIFTNYWIAWVRQMPGKGLSEMGIIYPGDSIDIRYSPSFQGGQVTISADKSITTAY	80
INN - anifro-HC	EVQLVQSGAEVKKPGESLKISCKGSGYIFTNYWIAWVRQMPGKGLSEMGIIYPGDSIDIRYSPSFQGGQVTISADKSITTAY	80
Consensus	LQWSSLKASDTAMYYCARHDIEGFDYWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTWNS	160
SEQ ID NO: 1_anifro-VH	LQWSSLKASDTAMYYCARHDIEGFDYWGRGTLVTVSS-----	160
SEQ ID NO: 3_anifro-HCDR1	-----	130
SEQ ID NO: 4_anifro-HCDR2	-----	111
SEQ ID NO: 5_anifro-HCDR2	-----HDIEGFDY-----	62
SEQ ID NO: 10_anifro-HFc	-----ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTWNS	43
SEQ ID NO: 11_anifro-HC	LQWSSLKASDTAMYYCARHDIEGFDYWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTWNS	160
INN - anifro-HC	LQWSSLKASDTAMYYCARHDIEGFDYWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTWNS	160
Consensus	GALTSVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEFEGGPSV	240
SEQ ID NO: 1_anifro-VH	-----	240
SEQ ID NO: 3_anifro-HCDR1	-----	210
SEQ ID NO: 4_anifro-HCDR2	-----	191
SEQ ID NO: 5_anifro-HCDR2	-----	142
SEQ ID NO: 10_anifro-HFc	GALTSVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEFEGGPSV	123
SEQ ID NO: 11_anifro-HC	GALTSVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEFEGGPSV	240
INN - anifro-HC	GALTSVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEFEGGPSV	240
Consensus	FLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNMVVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK	320
SEQ ID NO: 1_anifro-VH	-----	320
SEQ ID NO: 3_anifro-HCDR1	-----	290
SEQ ID NO: 4_anifro-HCDR2	-----	271
SEQ ID NO: 5_anifro-HCDR2	-----	222
SEQ ID NO: 10_anifro-HFc	FLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNMVVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK	203
SEQ ID NO: 11_anifro-HC	FLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNMVVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK	320
INN - anifro-HC	FLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNMVVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK	320
Consensus	CKVSNKALPASIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPVLD	400
SEQ ID NO: 1_anifro-VH	-----	400
SEQ ID NO: 3_anifro-HCDR1	-----	370
SEQ ID NO: 4_anifro-HCDR2	-----	351
SEQ ID NO: 5_anifro-HCDR2	-----	302
SEQ ID NO: 10_anifro-HFc	CKVSNKALPASIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPVLD	283
SEQ ID NO: 11_anifro-HC	CKVSNKALPASIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPVLD	400
INN - anifro-HC	CKVSNKALPASIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPVLD	400
Consensus	DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	447
SEQ ID NO: 1_anifro-VH	-----	117
SEQ ID NO: 3_anifro-HCDR1	-----	5
SEQ ID NO: 4_anifro-HCDR2	-----	17
SEQ ID NO: 5_anifro-HCDR2	-----	8
SEQ ID NO: 10_anifro-HFc	DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	330
SEQ ID NO: 11_anifro-HC	DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	447
INN - anifro-HC	DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	447

Figure 45

Consensus		EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFFAMVYQQKPGQAPRLLIYGASSRATGIPDRLSGSGSGTDFTLITRLE	80
SEQ ID NO: 2_anifro-VK		EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFFAMVYQQKPGQAPRLLIYGASSRATGIPDRLSGSGSGTDFTLITRLE	80
SEQ ID NO: 6_anifro-LCDR1		-----RASQSVSSSFFA-----	57
SEQ ID NO: 7_anifro-LCDR2		-----GASSRAT-----	30
SEQ ID NO: 8_anifro-LCDR3		-----	
SEQ ID NO: 09_anifro-LFc		-----	
SEQ ID NO: 12_anifro-LC		EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFFAMVYQQKPGQAPRLLIYGASSRATGIPDRLSGSGSGTDFTLITRLE	80
Consensus		PEDFAVYVCQQYDSSAITFGQGTIRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNS	160
SEQ ID NO: 2_anifro-VK		PEDFAVYVCQQYDSSAITFGQGTIRLEIK-----	160
SEQ ID NO: 6_anifro-LCDR1		-----	137
SEQ ID NO: 7_anifro-LCDR2		-----	110
SEQ ID NO: 8_anifro-LCDR3		-----QQYDSSAIT-----	71
SEQ ID NO: 09_anifro-LFc		-----RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNS	52
SEQ ID NO: 12_anifro-LC		PEDFAVYVCQQYDSSAITFGQGTIRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNS	160
Consensus		QESVTEQDSKDSITYSLSSITLTLISKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	215
SEQ ID NO: 2_anifro-VK		-----	108
SEQ ID NO: 6_anifro-LCDR1		-----	12
SEQ ID NO: 7_anifro-LCDR2		-----	7
SEQ ID NO: 8_anifro-LCDR3		-----	9
SEQ ID NO: 09_anifro-LFc		QESVTEQDSKDSITYSLSSITLTLISKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	107
SEQ ID NO: 12_anifro-LC		QESVTEQDSKDSITYSLSSITLTLISKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	215